Clinical Trial Update: Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of deferasirox combined with desferoxamine in transfusion-dependent beta-thalassemia patients with severe cardiac ir…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Cardiac Iron Overload

Drugs mentioned

• Deferasirox (Deferasirox)
• Desferoxamine (deferoxamine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Transfusion-dependent β-thalassemia Patients, Cardiac Iron Overload | Phase 2 | Status: TERMINATED | Results posted: 2019-10-23